newsfilter
← Latest News
GlobeNewswire·

SeaStar Medical Announces 2026 Milestones

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion